—

BIJHANS (BIJHANS) is currently trading at 109.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

BIJHANS operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.

Over the past 52 weeks, BIJHANS has traded between a low of ₹109.00 and a high of ₹111.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

BIJHANS has a market capitalization of approximately N/A. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

BIJHANS’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of N/A Cr, BIJHANS is classified as a N/A stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

BIJHANS operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of BIJHANS is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Arvaya Healthcare reported consolidated profit after tax of Rs 1.90 crore for the half year ended September 30, 2026. It reported profit before tax of Rs 1.88 crore and a tax credit of Rs 1.66 lakh.

Arvaya Healthcare completed the acquisition on November 1, 2026. It acquired 1,84,374 SIGPL equity shares, which represented 100% of SIGPL’s share capital. SIGPL became a wholly owned subsidiary from that date.

Arvaya Healthcare reported consolidated revenue from operations of ₹40.28 crore for Q2 FY27 ended 30 September 2026. This was 34.7% higher than ₹29.91 crore in Q1 FY27.

Arvaya Healthcare approved a draft letter of offer for a proposed partly paid equity rights issue of up to ₹210 crore. The document is intended for submission to BSE for in-principle approval.